Jos Melenhorst

1.2k total citations
14 papers, 678 citations indexed

About

Jos Melenhorst is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jos Melenhorst has authored 14 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Jos Melenhorst's work include CAR-T cell therapy research (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (4 papers). Jos Melenhorst is often cited by papers focused on CAR-T cell therapy research (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (4 papers). Jos Melenhorst collaborates with scholars based in United States, United Kingdom and Netherlands. Jos Melenhorst's co-authors include A. John Barrett, Giuseppe Sconocchia, Nancy F. Hensel, Katayoun Rezvani, A. John Barrett, Carl H. June, Hiroshi Fujiwara, Shannon L. Maude, Alexander E. Perl and Alison W. Loren and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Jos Melenhorst

14 papers receiving 675 citations

Peers

Jos Melenhorst

ONCOL

IMMUN

HEMAT

GENET

Dorothea Wessiepe Germany

Nobuhiko Imahashi Japan

Tatsunori Goto Japan

Susanne Hofmann Germany

Margot J. Pont United States

Cecilia Barese United States

Clare Taylor United States

Sibylle Pscherer Germany

Fengshuo Lan United States

Cuicui Lyu China

Dorothea Wessiepe Germany

Jos Melenhorst

497 ×1.3

ONCOL

198 ×0.6

IMMUN

117 ×0.6

HEMAT

50 ×0.5

GENET

79 ×0.8

Citations per year, relative to Jos Melenhorst Jos Melenhorst (= 1×) peers Dorothea Wessiepe

Countries citing papers authored by Jos Melenhorst

Since Specialization

Citations

This map shows the geographic impact of Jos Melenhorst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jos Melenhorst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jos Melenhorst more than expected).

Fields of papers citing papers by Jos Melenhorst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jos Melenhorst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jos Melenhorst. The network helps show where Jos Melenhorst may publish in the future.

Co-authorship network of co-authors of Jos Melenhorst

This figure shows the co-authorship network connecting the top 25 collaborators of Jos Melenhorst. A scholar is included among the top collaborators of Jos Melenhorst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jos Melenhorst. Jos Melenhorst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Wehrle, Chase J., Sofía Ferreira-González, Neda Dadgar, et al.. (2024). Tumor organoids for primary liver cancers: A systematic review of current applications in diagnostics, disease modeling, and drug screening. JHEP Reports. 6(12). 101164–101164. 5 indexed citations

Frey, Noelle V., Pamela A. Shaw, Elizabeth O. Hexner, et al.. (2019). Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 38(5). 415–422. 173 indexed citations

Ghassemi, Saba, Felipe Bedoya, Selene Nuñez-Cruz, et al.. (2016). Shortened T cell culture with IL-7 and IL-15 provides the most potent chimeric antigen receptor (CAR)-modified T cells for adoptive immunotherapy.. The Journal of Immunology. 196(1_Supplement). 214.23–214.23. 5 indexed citations

Ghassemi, Saba, Felipe Bedoya, Selene Nuñez-Cruz, et al.. (2016). 203. Shortened T Cell Culture with IL-7 and IL-15 Provides the Most Potent Chimeric Antigen Receptor (CAR)-Modified T Cells for Adoptive Immunotherapy. Molecular Therapy. 24. S79–S79. 11 indexed citations

Kennedy‐Nasser, Alana A., Stephanie Ku, Yasmin Hazrat, et al.. (2014). Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity. Clinical Cancer Research. 20(8). 2215–2225. 145 indexed citations

Szmania, Susann, Sacha Gnjatic, Guido Tricot, et al.. (2007). Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma. Journal of Immunotherapy. 30(8). 847–854. 32 indexed citations

Melenhorst, Jos, Nancy F. Hensel, Giuseppe Sconocchia, et al.. (2006). T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. Journal of General Virology. 87(10). 2951–2960. 62 indexed citations

Sconocchia, Giuseppe, Maurizio Provenzano, Katayoun Rezvani, et al.. (2005). CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines. Journal of Translational Medicine. 3(1). 15–15. 10 indexed citations

Sconocchia, Giuseppe, Maurizio Provenzano, Katayoun Rezvani, et al.. (2005). The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D–target-cell interactions. Blood. 106(10). 3666–3672. 70 indexed citations

10.

Sconocchia, Giuseppe, Hiroshi Fujiwara, Katayoun Rezvani, et al.. (2004). G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. Journal of Leukocyte Biology. 76(6). 1214–1219. 14 indexed citations

11.

Dang, Nam H., Ugur Aytac, Kazuya Sato, et al.. (2003). T‐large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. British Journal of Haematology. 121(6). 857–865. 27 indexed citations

12.

Battiwalla, Minoo, Jos Melenhorst, Yogen Saunthararajah, et al.. (2003). HLA‐DR4 predicts haematological response to cyclosporine in T‐large granular lymphocyte lymphoproliferative disorders. British Journal of Haematology. 123(3). 449–453. 46 indexed citations

13.

Fujiwara, Hiroshi, Frank El Ouriaghli, Matthias Grube, et al.. (2003). Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood. 103(8). 3076–3083. 35 indexed citations

14.

Smeets, H.J.M., Jos Melenhorst, Henny H. Lemmink, et al.. (1992). Different mutations in the COL4A5 collagen gene in two patients with different features of Alport syndrome. Kidney International. 42(1). 83–88. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact